Morgan Stanley lowers Hengrui Pharma's revenue and net profit forecast, target price raised to 92 yuan
Morgan Stanley has lowered its total revenue forecasts for Hengrui Pharma (01276.HK) for 2025 to 2027 by 2.1%, 3.7%, and 1.8%, respectively, mainly reflecting a decrease in commercial development revenue from GlaxoSmithKline assets and a decline in contributions from the generic drug business, partially offset by an upward revision in innovative drug sales forecasts; net profit forecasts have also been lowered by 7.4%, 8.9%, and 6.5%, respectively.
After updating the valuation time benchmark and adjusting the RMB to HKD exchange rate, the target price for Hengrui Pharma has been raised from 86 yuan to 92 yuan, maintaining an "Overweight" rating
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments